Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2023-04-27 Annual Report
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL 2022' (Annual Financial Report 2022) for Pherecydes Pharma. It includes a management report ('RAPPORT DE GESTION'), a table of contents covering business activities, financial results, risk factors, and corporate governance, and an attestation by the CEO. This document constitutes the comprehensive annual reporting package required for regulatory compliance, which falls under the '10-K' category in the provided schema. FY 2022
2023-04-27 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated April 17, 2023, announcing that Pherecydes Pharma presented analytical performance protocol data for its Phagogram 1.5 at the ECCMID congress. It discusses compliance with regulatory requirements (European directive 98/97/EC) and international standards (ISO 20776-2, FDA guidelines) related to an *in vitro* diagnostic test. This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific/technical progress and regulatory alignment presented at a conference. Since it details technical and regulatory achievements rather than a standard financial report, a board change, or a transaction, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate/scientific update that doesn't match the more specific categories like DIV, CAP, or MANG. Given the length (4952 chars) and content, it is a substantive announcement, not just a notice of publication (RPA).
2023-04-17 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 92% confidence The document is a press release dated April 17, 2023, announcing that Pherecydes Pharma presented analytical performance protocol data for its Phagogramme 1.5 at the ECCMID congress. It discusses regulatory compliance (CE-IVD directive) and analytical testing standards (ISO, FDA). This type of announcement, detailing scientific or regulatory progress presented at a conference, is typically classified as a general regulatory announcement or a specific update that doesn't fit the core financial reports (10-K, IR, ER). Since it is an announcement about scientific/regulatory progress rather than a formal financial report, capital change, or management change, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements. It is not a Call Transcript (CT), Earnings Release (ER), or Investor Presentation (IP) in the strict sense, but rather a news release about a presentation.
2023-04-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is a press release dated April 6, 2023, announcing that the brokerage firm TP ICAP Midcap initiated coverage on Pherecydes Pharma shares with a 'Buy' recommendation and a target price. This type of announcement, which relays external analyst ratings and research initiation, does not fit neatly into the specific categories like Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). It is a general corporate announcement related to investor relations and market perception. Since it is not a formal regulatory filing (like 10-K or DEF 14A) and doesn't fit other specific categories (like DIRS, DIV, or M&A), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements not covered elsewhere.
2023-04-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated April 6, 2023, announcing that TP ICAP Midcap has initiated research coverage on Pherecydes Pharma with a 'Buy' recommendation and a target price of 6.2 euros per share. This type of announcement, which details the initiation of analyst coverage, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a specific corporate action related to investor relations and market communication. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ), and it is not a presentation (IP) or a transcript (CT), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is a formal announcement disseminated to the market regarding external analyst coverage, which often falls under general disclosure requirements.
2023-04-06 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is titled "Pherecydes Pharma publie ses résultats financiers annuels 2022 et précise sa stratégie de développement pour 2023" (Pherecydes Pharma publishes its 2022 annual financial results and specifies its development strategy for 2023). It contains a detailed 'Compte de résultat simplifié' (Simplified Income Statement) for 2022 and 2021, discussing revenue, operating expenses, and net loss for the fiscal year ended December 31, 2022. This content clearly indicates a comprehensive annual financial report. Although it also discusses strategy and upcoming events (like the AGM date), the core of the document is the presentation of the full-year financial performance, which aligns best with the Annual Report (10-K) definition, even if it is a French equivalent document type. The footnote mentions that the full annual financial report will be available later, but this document itself contains the detailed annual results and management discussion, making it the primary annual financial disclosure. FY 2022
2023-03-30 French

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.